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ushilraut01@gmailAbstract Skin aging is an unavoidable aspect of human life. Premature skin aging can result from
poor care, environmental pollutants, and ultraviolet radiation exposure. Wrinkles, lines, spots,
uneven skin tone, and pigmentation are often indicators of skin aging. One cannot avoid aging but
cosmetics and pharmaceutical approaches can minimize and delay the damage. Topical applica-
tions of biocompatible and biodegradable vehicles have been explored for delivering anti-aging
compounds. Lecithin organogel (LO) is an effective vehicle for topical delivery of many bioactive
agents used in aging treatment. Lecithin is cell component isolated from soya beans or eggs and
puriﬁed to show excellent gelation in non-polar solvents when combined with water. LO can form a
heat-stable, resistant to microbial growth, visco-elastic, optically transparent, and non-birefringent
micellar system. It serves as an organic medium to enhance dermal permeation of poorly permeable
drugs by effectively partitioning into the skin. Its ability to dissolve in hydrophilic as well as in
lipophilic drugs makes it a dynamic vehicle, which can be explored as a carrier for anti-aging
agents.
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Bioactive agents in the treatment of skin aging 91. Introduction
Skin is one of the most important organs of the human body
with important protective functions. One of the most prominent
problems associated with skin is aging. Skin aging has been
deﬁned as the amassing of skin damage over time1. Although
each part of the body ages with the time, skin is the external
organ where the signs and symptoms of aging are readily
evident2. However, skin aging can be delayed by cosmetics as
well as by pharmaceutical approaches. The permeation of
exogenous substances, including agents used in treating skin
aging, is prevented by the barrier function of skin. Therefore,
the major challenge for topical formulations today is to provide
a sufﬁcient increase in drug penetration into skin without
causing irreversible alterations to the barrier function3–5.
Bioactive agents or drugs cross the skin barrier by two
mechanisms: transcellular and paracellular transport. Lipo-
philic agents move across the barrier by a transcellular
mechanism whereas hydrophilic agents are likely to follow a
paracellular pathway to cross the skin6. Various creams,
ointments, lotions, as well as gels are available and marketed
for skin aging treatment. It was found that lipid-based
formulations work most efﬁciently by improving penetration
through the skin, but the drawback associated with such
formulations is that they alter the hydration state of the skin,
which may result in dermatitis. In contrast, water-based
formulations are able to maintain the bioactive state of skin
but exhibit poor penetration7,8.
Lecithin organogels (LO) are promising vehicles to deliver
wide variety of agents through the skin because they possess
both the properties of oil and aqueous based formulations9. In
this review we focus on the potential of LO to deliver bioactive
agents in the treatment of skin aging.2. Skin aging and molecular mechanisms
There are two different types of aging: intrinsic aging and
extrinsic aging. Intrinsic aging occurs inevitably as a natural
consequence of physiological changes over time at variable
yet inalterable genetically determined rates. Extrinsic aging is
caused by environmental factors such as repetitive facial
expressions, gravity, sleeping positions, smoking and exposure
to the sunlight. The frequently visible features of intrinsic
aging are ﬁne wrinkles, thin and transparent skin, hollowed
cheeks and eye sockets, loss of ﬁrmness on the hands and
neck, sagging, dry skin that may itch, inability to sweat
sufﬁciently, graying hair that eventually turns white, and hair
loss. Extrinsic factors, especially sun exposure, often act
simultaneously with the normal aging process and cause
earlier skin aging. Photoaging is the term principally applied
to depict extrinsic aging caused by sun exposure. Photoaging is
often indicated by age spots, spider veins on the face, rough
and leathery skin, ﬁne wrinkles that disappear when stretched,
loose skin, a blotchy complexion, solar elastosis, actinic
keratosis, and skin cancer10,11.
Skin aging is generally accelerated by reactive oxygen
species that result from the oxidation of cellular components.
Reactive oxygen species include superoxide, hydroxyl radicals,
hydrogen peroxide, singlet oxygen, etc. Generation of endo-
genous reactive oxygen species takes place under mental as
well as physical stress12,13. The major sources of free radicalgeneration include prostaglandin synthesis, phagocytosis,
cytochrome P-450 enzymes, non-enzymatic reactions of oxy-
gen, and ionizing radiation, which damage the molecular
structure of DNA, proteins, lipids, and prostaglandins14,15.
Collagen type I is the most abundant protein of the skin
connective tissue present in the dermal extracellular space,
where it undergoes enzymatic processing. The formation of
collagen bundles is responsible for the strength and resiliency
of the skin16–18. Smoking increases the production of collage-
nase, which breaks down the collagen and causes premature
wrinkling19–21. UV radiation also affects the synthesis of
collagen and elastin and changes gene activity by altering
signal transduction cascades22. Certain hereditary factors and
lack of nutrients can also affect skin aging23,24.
Generally two mechanisms are involved in natural skin
defense: the ﬁrst is enzymatic, including glutathione peroxidase,
glutathione reductase, glutathione transferase, catalase, copper-
zinc superoxide dismutase, manganese superoxide dismutase,
and extracellular superoxide dismutase; the second is none-
nzymatic, including low-molecular weight compounds such as
ascorbate, glutathione, b-carotene, a-tocopherol, uric acid, and
bilirubin, all of which act as free radical scavengers25–27.3. Treatment of skin aging
A variety of agents have been tested and are commonly used
in the treatment of aging (Table 1). They can help relieve the
signs and symptoms of aging through various mechanisms.
Broadly, they are delivered as pharmaceuticals, cosmetics, and
cosmeceuticals.4. Concept behind the use of organogel for topical delivery
In order to confront skin aging, all the agents listed above were
tested in patients systemically as well as locally. It has been
reported that various systemic anti-aging agents required rela-
tively large doses and caused dose-dependent toxicity in many
cases. Kockaert et al.42 discovered that oral administration of
vitamin A will result in hypervitaminosis A. Also, some drugs
undergo ﬁrst-pass metabolism, which prevents their delivery to
the desired site of action. De la Lastra et al.43 showed that
resveratrol by oral administration undergoes ﬁrst-pass metabo-
lism. Because of the short half-life, repeated dosing is necessary.
Many drugs undergo degradation by gastric acid as well as gut-
wall enzymes. Proteins and peptides used in aging treatment can
be degraded by the gastric acid and enzymes44. Furthermore,
many hydrophilic or lipophilic drugs show either poor dissolu-
tion or poor absorption on oral administration45. Patients are
not always in favor of oral as well as parenteral dosage forms.
Parenteral delivery causes pain because of invasiveness and a
skilled person is needed to deliver the injection. Also, in the case
of both oral and parenteral drug delivery, drug effects cannot be
stopped once administered. All these shortcomings restrict the
use of oral and parenteral dosage forms.
Topical delivery of drugs treating skin aging is most
favorably accepted nowadays46. Patients usually tend to pay
more attention to topical dosage forms because of the
convenient administration. No skilled person is required for
administration and drugs will not be degraded by acid or
enzymes. The effective concentration can be applied at the
Table 1 Various bio-active agents used in the treatment of skin aging.
Bioactive agents Mechanism
Vitamin C, vitamin E, co-enzyme Q10, ferulic acid, Free radical scavenging and inhibitors of lipid peroxidation28,29
green tea, idebenone, pycnogenol, silymarin
Hydroquinone and its derivatives, glycolic acid, malic acid, Inhibit production of melanin30
citric acid, mixed fruit acid, triple fruit acid and sugar
cane extract
Lactic acid Hydration of the stratum corneum and prevention of skin
damage31
Para-aminobenzoic acid derivatives, cinnamates, salicylates, UV ﬁlters32
octocrylene, ensulizole, benzophenones, retinoids,
butyl methoxydibenzoyl and meradimate
Vitamin A Reduces collagen breakdown by inhibiting the
metalloproteinases33,34
Vitamin B Anti-inﬂammatory effect and anti-acne action35,36
N-acetyl glucosamine (NAG) and glucosamine Build skin structural matrix37–39
Metals (zinc, copper, selenium) Link with proteins superoxide dismutase and metallothionein
and act as anti-oxidants40
Soyabean derivatives Inhibit protease activated receptor 2 (PAR-2)41
Figure 1 Structure of lecithin.
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metabolism. In addition, the termination of the topical
therapy is easily accomplished. In skin aging treatment, topical
dosage forms such as creams, ointments, lotions, linaments
and gels are commonly available in the market because of
their features including appearance, ease of application, ease
of removal, effective at the site of action, and lessened side
effects compared to oral and parenteral dosage forms. Many
varieties of cosmetic products are available in the market and
are commercially advantageous. Nonetheless, cosmetic pro-
ducts even after the various safety tests may cause some
undesirable effects including dermatoses47. But the use of
natural and bio-friendly drug-loaded vehicles can help relieve
such problems. Hence, researchers seek to develop novel
vehicles that are natural, biocompatible, non-immunogenic,
non-allergic, and effective for the patients. For manufacturers,
desirable features include ease of manufacture, long-term
stability, and ready quality control.
Gels are best ﬁtted in all these essential criteria because of
their excellent appearance, smoothness, desired consistency,
fast drug release, ease of manufacturing and quality assess-
ment, and admirable stability. The United States Pharmaco-
poeia (USP) deﬁned gels as semisolids, either suspension of
small inorganic particles or large organic molecules interpene-
trated with liquid48. Gels are transparent or translucent
semisolid formulations containing a high ratio of solvent/
gelling agent. When dispersed in an appropriate solvent,
gelling agents merge or entangle to form a three-dimensional
colloidal network structure, which limits ﬂuid ﬂow by entrap-
ment and immobilization of the solvent molecules49. Recently,
gel formulations have been modiﬁed to yield an advanced drug
delivery system known as ‘‘organogels’’, which is composed of
organic as well as aqueous phases possessing various beneﬁcial
properties.5. Lecithin organogels
LOs are gels consisting of an organic medium in liquid phase. LOs
are thermodynamically stable, clear, viscoelastic, biocompatibleand isotropic gels which are composed of lecithin (Fig. 1), an
organic solvent, and a polar liquid. LO have jelly-like structure
that consists of three-dimensional networks of entangled reverse
cylindrical micelles, which immobilize the continuous phase and
thus convert from liquid to viscous gel50.
Traditionally, organogel systems are applied topically when
the active agent is oil-soluble or penetration into the deeper
skin layer is required. Surfactants act as penetration enhancers
that alter the membrane bilayer structure and thus reduce
the diffusion barrier and enable the drug to penetrate deeply
into skin51. Since the discovery of simple gelator molecules,
organogels have attracted increasing attention. These novel
formulations can be used in small quantities without further
additives, resulting in more biocompatible products52. A wide
variety of organogels have been developed by researchers and
classiﬁed based on the nature of the organogelators, such as
LO, gelatin-stabilized organogels, limonene GP1/PG organo-
gel, non-ionic surfactant based organogels and polyethylene
organogels53. Among these organogels, LOs are a unique
micellar system composed of a non-polar oil phase, an
aqueous polar phase, and a surfactant phase, which is derived
from soy or egg lecithin. Self-assembly of lecithin molecules in
nonaqueous media into reversed giant cylindrical micelles
occurred when small amounts of water, glycerol, or forma-
mide are added. LO was ﬁrst introduced by Scartazzini and
Luici in 198854. They observed that the addition of small
amount of water into nonaqueous solutions of naturally
occurring lecithin caused a sudden rise in the viscosity55.
The chemical name of lecithin is 1,2-diacyl-sn-glycero-3-
phosphatidylcholine.
Lecithin is a complex mixture of acetone-insoluble phospha-
tides, which mainly consist of phosphatidyl choline, phosphatidyl
Figure 2 Arrangement of lecithin molecules in micellar systems.
Bioactive agents in the treatment of skin aging 11ethanolamine, phosphatidyl serine, and phosphatidyl inositol
combined with different amounts of other substances such as
triglycerides and fatty acids56. The main sources of lecithin are
soya beans and egg yolk. Lecithin varies greatly in its physical
form, from viscous semi-liquid to powder depending on the
content of free fatty acid. It may also vary in color from brown
to light yellow depending on whether it is bleached or
unbleached57. Lecithin is available in various marketed grades
like EPIKURON, LIPOID S 100, and CAPCITHIN, which are
derived and puriﬁed from either soya beans or eggs. Desired
gelation in organic solvent occurs only when the lecithin contains
more than 95% phosphatidylcholine and is free from fat as well
as moisture. Lecithin is a multi-functional surface-active agent.
The lecithin molecule can be divided into two portions, the fatty-
acid portion, which is attracted to lipophilic drugs, and the
phosphoric acid portion, which is attracted to hydrophilic drugs.
Because of these two aspects, lecithin molecules arrange them-
selves at the boundary between immiscible liquids such as oil and
water (Fig. 2). This arrangement reduces the interfacial tension
between oil and water and makes relatively stable emulsions.
Poorly puriﬁed lecithin or synthetic lecithins do not exhibit
gelation properties54.
Lecithin is an important component of all living cells and is
recognized by Food and Drug Administration as GRAS
(Generally Regarded As Safe, 21 CFR 184, 1400). Its unique
lipid molecular structure (Fig. 1) performs versatile functions.
It has a wide variety of roles in pharmaceuticals, cosmetics
and food industries as an emulsiﬁer, viscosity modiﬁer,
stabilizer, solubilizer and penetration enhancer58.5.1. Composition of LO
LO is composed of a biosurfactant (lecithin), which acts as a
gelling agent and a non-polar organic media as external or
continuous phase and a polar agent (usually water)59,55.
Lecithin is a biocompatible and biodegradable surfactant as
well as a cellular component, which acts as a penetration
enhancer60. Lecithin contains phospholipid molecules, which
are self-assembled to build up the microstructure of organogel.
The unsaturated non-polar part of lecithin molecules can affect
the critical packing parameter (CPP). It contributes in the
development of reverse micellar structures and furthermore
converts these micelles to three-dimensional long tubular net-
works61. Organic solvent plays a vital role in organogel by
providing the desired solvent action for drug as well as lecithin,
and supported its skin penetration enhancing property9,62,63.
Many organic solvents are available for LO, and include ethyl
laureate, ethyl myristate, isopropyl myristate, isopropyl palmi-
tate, cyclopentane, cyclooctane, trans-decalin, trans-pinane,
n-pentane, n-hexane, n-hexadecane, and tripropylamine. Itwas observed that they are effective in permeation of drug into
skin but they exhibit toxicological manifestations61. Generally
biocompatible and biodegradable organic solvents are preferred
because of their safety in use. Natural oils including soyabean oil,
sunﬂower oil, rape seed oil and mustard oil possess desired
properties as a solvent in LO55. The polar component acts as
structural, gel forming and stabilizing agent. The gel-forming
ability of the polar solvent depends on its physicochemical
properties such as surface tension, dielectric constant and
polarity. Water, glycerol, ethylene glycol and formamide have
strong gelling potential64. Among all these polar solvents, water
is a very effective and natural polar agent, which is beneﬁcial for
skin hydration and maintains the vitality of the skin. It can
hydrate the upper skin layer (stratum corneum), which is a dead,
keratinized and compact layer. In addition to the above-
mentioned components, some other agents like co-surfactants
and anti-oxidants are also incorporated in LO to boost its
effectiveness. Co-surfactants such as n-butanol and propylene
glycol provide thermodynamic stability as well as ﬂexibility to the
micellar system in LO. Co-surfactant lowers the interfacial
tension between the nonpolar and polar phase and also enhances
skin permeability65–67. Oils used in LO may undergo oxidation,
which will affect the stability of LO. Hence, antioxidants like
ascorbic acid are usually incorporated for stability.
5.2. Phenomenon of organogelation of lecithin
The gelation process (Fig. 3) in organogel takes place with the
addition of a trace amount of water into the lecithin solution
of organic solvent. Initially, the lecithin molecules are ran-
domly dispersed in the organic medium. With the addition of
small amount of water, the lecithin molecules will assemble in
spherical reverse micellar form. Further addition of water
makes the short tubular or cylindrical micellar aggregate.
The water molecules bind stoichiometrically to the hydrophilic
head of the lecithin molecules. Thus they act as a bridge between
two adjacent lecithin molecules to form the linear networks with
the hydrogen bonds between polar molecules and phosphate
groups of lecithin molecules. A further increase in a small amount
of water results in the formation of long, ﬂexible and worm-like
tubular micellar structures (Fig. 4). Thousands of such tubular
micro-structures overlap and entangle with each other to form a
three-dimensional gel network, which possesses viscoelasticity and
thermo-reversibility. The organic liquids get entrapped in the
spaces between the entangled reverse micelles68–70.
5.3. Beneﬁcial properties of LO
5.3.1. Hydrophiliclipophilic balance
LOs are well balanced with hydrophilicity and hydrophobi-
city, as they are composed of oil and water. It can dissolve a
wide variety of guest molecules. Hydrophilic drugs dissolve in
polar phase and lipophilic drugs dissolve in the non-polar
phase. Lecithin molecules are amphiphilic in nature and
possess polar headgroups, which attract the polar drugs and
non-polar tails, which solubilize nonpolar drugs44.
5.3.2. Microbial resistance
Micro-organisms grow well in aqueous environments but
growth is inhibited in non-aqueous environments. With LO,
the external phase is non-aqueous and the internal aqueous
Figure 4 Micro-structure of organogel with long tubular network.
Figure 3 Process of organogelation.
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contamination71.5.3.3. Non-birefringence and optical transparency
LO is isotropic as it appears as a one-phase system. Optically,
it is transparent and provides the beneﬁt of visual inspection
so that the presence of any particulate matter can be easily
recognized9,72.5.3.4. Safety and biocompatibility
LO containing non-polar components such as di-butyl ether,
cyclopentane, cyclo-octane, trans-decalin, trans-pinane, n-pen-
tane, n-hexane, and n-hexadecane may cause some allergic
and immunological reactions and chronic dermatoses whenapplied to the skin for long-term use. However, the use of
biocompatible oils such as soyabean oil, sunﬂower oil, rape
seed oil, or mustard oil can minimize such problems. Water as
the internal phase can maintain the bioactive state of the skin
by hydrating it. Lecithin is biocompatible in nature and is a
component of cell membranes. The use of lecithin in organogel
is safe. From the results of skin compatibility studies it was
revealed that topical use of LO is safe55,61.
5.3.5. Thermostability
In the organogel lecithin acts as a gelator molecule, which can
be self-assembled after addition of water. When the tempera-
ture of organogel system increases, lecithin molecules absorb
kinetic energy, minimizing the loss of organogel structure. At
lower temperatures lecithin molecules reassemble, and there-
fore LOs are inherently thermostable and valuable for the
delivery of bioactive agents and for cosmetic applications73.
5.3.6. Viscoelasticity
The viscous and elastic nature of LO follows the Maxwell
model of viscoelasticity74. When the organogels were sheared
at low shear rates, they behave like a solid and show an elastic
property. With a subsequent increase in shear rate, the tubule
structures are weakened. The gelator molecules break the
physical interactions from the tubule until the shear stress is
high enough to destroy the organogel structure. This behavior
is termed as plastic ﬂow behavior75.
5.4. Phase behavior of LO
A pseudo-ternary diagram (Fig. 5) was constructed for the
lecithinoilwater system. It is constructed by titrating the
dispersion of lecithin in oil with water in differing concentration
Figure 5 Lecithinoilwater phase diagram with lecithinoil
ratio of 60:40 (w/w).
Table 2 Dermal delivery of various bioactive agent
using LO.
Category Bioactive agents/drugs
Vitamins Vitamin A and C77
NSAIDS Diclofenac, ibuprofen,
ketoprofen, indomethacin,
piroxicam, aceclofenac9,77,78
Anti-vitiligo agents Methoxsalen, triosalen,
corticosteroids, calcineurin
inhibitors82
Anti-scars Sphingosine, sphinganine,
phytosphinosine,
N-acetylsphingosine,
N-hexanoylsphingosine,
curcumin, apigenin83
Skin lightners Kojic acid, azelaic acid, glycolic
acid84
Anticholinergic Scopolamine78
b-Adrenergic agonist Broxaterol78
Anti cancer Aromatic tetra-amidines85
Anti-hypertensive Nicardipine85
Psychopharmaceuticals Fluoxetine, ertraline,
paroxetine, amitriptyline,
trazadone86
Others Amino acids and peptides78,
botulinium toxins85
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phase diagram provides information for the boundaries of the
different phases as a function of composition variables and
temperatures. Concentrations of lecithin, oil, and water are
extremely critical in organogel system. Initially, water in oil
micro-emulsion was stabilized by lecithin micelles formed with
low concentration of water, which is characterized by optical
transparency and low viscosity. As the amount of water
increases, the micro-emulsion turned to a viscous gel. Thus, the
organogel system is also called a micro-emulsion-based organo-
gel. Phase diagrams for the organogel system also demonstrate
the behavior of organogel system such as cloudiness, isotropicity,
optical transparency, and viscosity. It was found that an excess
amount of water makes the system turbid; hence the concentra-
tion of water plays very crucial role in the production of a clear
organogel76.6. LO in dermal drug delivery
LO meets all the essential criteria for effective drug delivery.
Studies of LO have explored its potential as an efﬁcient matrix
for dermal administration of many bioactive agents. As the
lecithin itself provides skin protection against UV-induced
skin aging, it shows additive effects along with incorporated
bioactive agents against skin aging. A wide variety of guest
molecules such as vitamins A and C, hormones, NSAIDS,
peptides, amino acids, local anesthetics and antifungal agents
were reported to be effective topically as well as transdermally
when delivered by LO (Table 2). Histological evidence indi-
cated that no toxicological manifestations were present even
upon the prolonged application on the skin. Drugs are either
hydrophilic or lipophilic in nature, but LO can solublize both
types of the drugs. LO provides an effective permeation
through the skin by ﬂuidizing the membrane lipids as well as
by a hydration mechanism. The occlusive nature of LO
provides smooth feel on dermal application9,77,78. Shaikh
et al.79 reported that LO was found to be more effective and
safer for delivery of aceclofenac when compared with hydro-
gels. Fujii et al.80 performed experiments on rat skin revealing
that the permeation of indomethacin was greater with LO. Zia
et al.72 developed lecithin-stabilized microemulsion-based orga-
nogels for topical application of ketorolac tromethamine usingsoya lecithin as surfactant and isopropyl myristate as oil. It was
observed that LO solubilized higher concentrations of ketor-
olac tromethamine and that its release rate from LO was also
enhanced on guinea pig skin. Thus LO was a desirable drug
delivery vehicle for water soluble drugs and is capable of
providing an appropriate drug release pattern72. One of the
marketed products of J.A.R. Pharmaceuticals, Ltd. (Edmon-
ton, Alberta, Canada) is Phlojels Ultra, which is a LO
formulated to have cosmetic properties. It is non-greasy and
improves skin penetration of incorporated active ingredients.
After application to the skin, it is rapidly absorbed without any
residue. It has been widely accepted as a superior vehicle for
delivering drugs across the skin barrier. By applying the LO
formulation, the amount of drug needed to achieve a relatively
high local concentration is greatly decreased81.7. Conclusions
LO provides a new perspective for the topical delivery of anti-
aging agents. LO exhibits many desirable physicochemical
properties essential for topical vehicles. It can dissolve both
hydrophilic and lipophilic drugs and hence acts as effective
vehicle to deliver wide variety of drugs across the skin. It is
easy to prepare and handle. As LO contains ingredients that
are natural, biocompatible, safe and stable, it is likely to play
an increasingly important role in cosmetics as well as phar-
maceutical agents in treating skin.
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